Bio-Gene Technology Limited announced the following executive changes: Mr. Tim Grogan has been appointed Managing Director, effective from 28th August 2023. Mr. Richard Jagger formally resigns as current Managing Director to transition to a new advisory role focused on stakeholder management of Bio-Gene's existing and future development partnerships at the end of September. Tim brings more than 30 years' experience and expertise to Bio-Gene, with a successful track record of delivering growth in the agtech, food and human health sectors.

Tim has deep multi-disciplinary experience in the management of new product development, commercialisation, capital raising and corporate governance. As a hands-on leader, Tim has held several key executive roles, specialising in product development and expanding business partnerships. As CEO of SIRA Pty Ltd, Tim led the commercial development of technologies to produce new types of healthier sugar.

Prior to this, Tim was the CEO of Dimerix BioScience Pty Ltd, where he managed the development of a novel treatment for diabetic nephropathy and the company completed three substantial pharmaceutical partnering deals within 12 months and significantly expanded its investor base. Tim also has extensive listed company experience, including with pharmaceutical development company, Starpharma, where he worked to steer it through the IPO process and establishing several commercial relationships globally. Most recently, Tim has been consulting to companies in the health and medical technology sectors in Australia, providing strategic, government and regulatory advice.

Tim holds a Bachelor of Law and a Bachelor of Science, majoring in chemistry, from the University of Melbourne.